Lifeward Ltd. Material Event - What Happened

This report explains the latest news from Lifeward Ltd. in plain English. We have removed complex financial jargon to help you understand what is happening and why it matters.

---

1. What happened?

Lifeward Ltd. has officially completed its acquisition of Oratech Pharma for $25 million. Alongside this purchase, the company expanded its board of directors from five to seven members to integrate new leadership.

2. When did it happen?

The acquisition and board changes became official on March 25, 2026, following final approval from regulators and shareholders.

3. Why did it happen?

Lifeward, which specializes in medical robotics and exoskeletons, is using this deal to move into medical treatments that complement its existing hardware. By bringing Oratech into the fold, they aim to offer a more integrated approach to patient care.

To fund the $25 million price tag, Lifeward used a mix of financing:

• Stock: They issued 4.2 million new shares and 1.5 million warrants.
• Debt: They took on $10 million in debt that carries a 6% interest rate and matures in 2031.

As part of the leadership transition, two longtime board members stepped down, and two representatives from Oratech joined the board to oversee the integration process.

4. Why does this matter?

Think of this as combining two toolboxes to build a more comprehensive product line. While this expansion could open new revenue streams, it comes with two significant trade-offs for current investors:

• Dilution: Issuing 4.2 million new shares increases the total share count by 18%. This means your "slice of the pie" as an existing shareholder is now smaller than it was before the deal.
• Financial Pressure: The $10 million in new debt adds $600,000 in annual interest expenses. Because this debt can be converted into stock, there is a possibility of even more shares being issued in the future if the stock price performs well.

5. Who is affected?

• Investors: Your ownership percentage has been diluted. The market will be watching closely to see if Oratech can generate the $5 million in additional annual revenue required to comfortably cover the new interest costs.
• Customers: It is business as usual for now. However, the company is under increased pressure to drive sales of its core ReWalk and AlterG products to support the new debt load.
• Employees: With new board members in place, expect changes in operations as the company merges sales teams and administrative departments.

6. What happens next?

Lifeward is now focused on merging Oratech’s operations into its own, with a goal to finish by the end of 2026. Keep an eye on the Q2 2026 financial report; it will be the first real look at how the new debt and revenue-sharing agreements are impacting the company’s cash flow and bottom line.

7. What should investors know?

This is a "wait and see" moment. Lifeward has traded immediate ownership (through dilution) and long-term debt to fund this growth. The most important question for investors now is whether this deal makes the company more profitable, or simply larger.

Decision Tip: Look for updates in the next quarterly report regarding "integration progress." If the company struggles to hit revenue targets, the cost of this debt could become a significant burden on the stock price.

---

Disclaimer: This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.